Axsome Therapeutics Inc

Senior Manager, CRM Systems Administration

United States

Axsome Therapeutics Inc Logo
Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceutical, BiopharmaceuticalIndustries

Requirements

Candidates should possess a Bachelor's degree in Computer Science, Information Systems, or a related field, and have at least 8 years of experience in CRM Systems Administration, with a strong focus on Salesforce. Demonstrated experience in the pharmaceutical industry, particularly life sciences, is preferred. Strong knowledge of regulatory requirements such as 21 CFR Part 11 / EU Annex 11 and GDPR is required, along with experience in data management and system maintenance.

Responsibilities

The Senior Manager, CRM Systems Administration will act as a Business Analyst, collaborating with commercial teams to understand their processes and translate them into effective Salesforce solutions. They will be responsible for user and license management, including new user setup and deactivation, role configuration, and permission management, as well as Salesforce configuration changes such as Flow, assignment rules, and reporting. The role also includes managing sandbox environments, participating in DevOps/release management, identifying and gathering requirements, creating a platform roadmap, and proactively maintaining the system through security reviews and updates. Furthermore, they will provide user support, create technical documentation, manage integrated applications, and support master data governance for commercial business processes.

Skills

Salesforce
CRM
Business Analysis
User and License Management
Salesforce Configuration
Flow
Assignment Rules
Approval Processes
Fields
Page Layouts
Record Types
Dynamic Layouts
Apps
Actions
Custom Settings
Mobile Administration
Dashboards
Reports
Data Loader
DevOps
Release Management
Requirements Gathering

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Key Metrics

New York City, New YorkHeadquarters
2012Year Founded
$430.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Performance Bonus
Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.
Potential delays in AXS-07 launch amid growing market anticipation.
Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.
AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI